A carregar...
Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation
There are limited data on direct‐acting antiviral (DAA) treatment options for previously treated patients with recurrent genotype 3 (GT3) hepatitis C virus (HCV) after liver transplantation. Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is currently approved for treatment of HCV in patients with...
Na minha lista:
| Publicado no: | Hepatol Commun |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6287482/ https://ncbi.nlm.nih.gov/pubmed/30556034 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1280 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|